Difference between revisions of "Part:BBa K3496006"
 
(4 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K3496006 short</partinfo>
 
<partinfo>BBa_K3496006 short</partinfo>
  
−
  This is a eriodictyol producing composite part, a collection of BBa_K1033001 (4CL), BBa_K1497001 (CHS),
+
===Usage and Biology===
−
BBa_K1497000 (CHI), BBa_K3496005 (F3‘H), aiming to biosynthesis Eriodictyol in Saccharomyces cerevisiae and improve the existing part BBa_K1497017.BBa_K1497017 is another composite part Naringenin producing operon under the T7 promoter.  
+
This is a eriodictyol producing composite part, a collection of BBa_K1033001 (4CL), BBa_K1497001 (CHS), BBa_K1497000 (CHI), BBa_K3496005 (F3‘H), aiming to biosynthesis Eriodictyol in Saccharomyces cerevisiae and improve the existing part BBa_K1497017.BBa_K1497017 is another composite part Naringenin producing operon under the T7 promoter.  
−
<br/>
+
 
−
<br/>
+
 
−
  Firstly, in terms of final product, compared with Naringenin, Eriodictyol has one more hydroxyl group on the B ring and higher anti-oxidation activity and higher Medicinal Value for health care.
+
Firstly, in terms of final product, compared with Naringenin, Eriodictyol has one more hydroxyl group on the B ring and higher anti-oxidation activity and higher Medicinal Value for health care.
−
<br/>
+
 
−
<br/>
+
 
−
  Secondly, since in the last step of eriodictyol metabolic pathway when P450 enzyme F3‘H hydroxylated naringenin to obtain the final product eriodictyol, it is supposed to happen in eukaryotic organisms instead of a prokaryotic cell which is unable to provide the membrane structure required for post-modification of the enzyme. As the biological chassis, Saccharomyces cerevisiae meets the need.
+
Secondly, since in the last step of eriodictyol metabolic pathway when P450 enzyme F3‘H hydroxylated naringenin to obtain the final product eriodictyol, it is supposed to happen in eukaryotic organisms instead of a prokaryotic cell which is unable to provide the membrane structure required for post-modification of the enzyme. As the biological chassis, Saccharomyces cerevisiae meets the need.
−
<br/>
+
 
−
<br/>
+
 
−
  Thirdly, when we look at the entire pathway throughout，this improved part is coordinating with enzyme TAL in E. coli which addresses the separation of metabolic pathways. The sharing of the burden of gene expression as well as the cross-feeding of metabolites, together improve metabolic efficiency and robustness to achieve high‐efficiency bioproduction of the final product.
+
Thirdly, when we look at the entire pathway throughout，this improved part is coordinating with enzyme TAL in E. coli which addresses the separation of metabolic pathways. The sharing of the burden of gene expression as well as the cross-feeding of metabolites, together improve metabolic efficiency and robustness to achieve high‐efficiency bioproduction of the final product.
−
<br/>
+
 
−
<br/>
+
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
−
===Usage and Biology===
 
  
 
<!-- -->
 
<!-- -->

Latest revision as of 09:48, 27 October 2020


Eriodictyol producing composite part

Usage and Biology

This is a eriodictyol producing composite part, a collection of BBa_K1033001 (4CL), BBa_K1497001 (CHS), BBa_K1497000 (CHI), BBa_K3496005 (F3‘H), aiming to biosynthesis Eriodictyol in Saccharomyces cerevisiae and improve the existing part BBa_K1497017.BBa_K1497017 is another composite part Naringenin producing operon under the T7 promoter.


Firstly, in terms of final product, compared with Naringenin, Eriodictyol has one more hydroxyl group on the B ring and higher anti-oxidation activity and higher Medicinal Value for health care.


Secondly, since in the last step of eriodictyol metabolic pathway when P450 enzyme F3‘H hydroxylated naringenin to obtain the final product eriodictyol, it is supposed to happen in eukaryotic organisms instead of a prokaryotic cell which is unable to provide the membrane structure required for post-modification of the enzyme. As the biological chassis, Saccharomyces cerevisiae meets the need.


Thirdly, when we look at the entire pathway throughout，this improved part is coordinating with enzyme TAL in E. coli which addresses the separation of metabolic pathways. The sharing of the burden of gene expression as well as the cross-feeding of metabolites, together improve metabolic efficiency and robustness to achieve high‐efficiency bioproduction of the final product.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 1108
    Illegal NheI site found at 2239
    Illegal NheI site found at 4621
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 1675
    Illegal BglII site found at 2248
    Illegal XhoI site found at 3201
    Illegal XhoI site found at 4848
    Illegal XhoI site found at 4877
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 2219
    Illegal NgoMIV site found at 2795
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 2168
    Illegal BsaI.rc site found at 1307
    Illegal BsaI.rc site found at 3605
    Illegal BsaI.rc site found at 4851